News & Press

Filter by year:

GeNeuro: Q3 2018 business review and cash position at 30 September 2018

Geneva, Switzerland, 24 October 2018 – 07:00am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes, has reviewed its business activity in Q3 2018 and announced its cash position at 30 September 2018.

GeNeuro Confirms Potential of Novel pHERV-K Antibodies for ALS in collaboration with NINDS, Secures Rights

Geneva, Switzerland, October 17, 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that following a successful collaboration in preclinical amyotrophic lateral sclerosis (ALS) models, the Company has signed an exclusive worldwide license with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH). The agreement covers the development of an antibody program to block the activity of pHERV-K Env (pathogenic envelope protein of the HERV-K family of Human Endogenous Retroviruses), a potential key factor in the development of ALS.

GeNeuro Presents Phase 2b Data Demonstrating Neuroprotective Effect of GNbAC1 in Multiple Sclerosis Patients at ECTRIMS 2018

Geneva, Switzerland, and Berlin, Germany, 15 October, 2018 – 7:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) announced today that data from its CHANGE-MS Phase 2b study of GNbAC1, a novel and promising therapeutic approach for the treatment of multiple sclerosis (MS), demonstrating a consistent effect on key neuroprotection endpoints was presented at the 34th Congress of the European Committee for Treatment and Research on Multiple Sclerosis (ECTRIMS 2018). The data showed that GNbAC1 administration for 12 months had a significant positive impact on key neuroprotection markers known to be linked to disease progression. Importantly, further analysis showed that these neuroprotective effects were at least as prominent in the inactive subpopulation, the precise group of patients who are not served well with currently-available disease modifying treatments. GNbAC1 is a monoclonal antibody designed to neutralize a pathogenic protein encoded by a member of the human endogenous retroviruses (HERV-W) family, pHERV-W Env.

GeNeuro to Present 12 Month Data on Anti-neurodegeneration Effects of GNbAC1 from CHANGE-MS Phase 2b Study in Multiple Sclerosis at ECTRIMS 2018

Geneva, Switzerland, October 10 2018 at 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) announced today that 12-month data from the CHANGE-MS Phase 2b study of GNbAC1 in multiple sclerosis (MS) will be presented in an oral presentation at the 34th Congress of the European Committee for Treatment and Research on Multiple Sclerosis (ECTRIMS 2018) meeting held 10-12 October 2018, in Berlin, Germany. The presentation will cover the results of this 270-patient study, measuring through MRI the anti-inflammatory and neuroprotective effects of GNbAC1, an antibody neutralizing the pHERV-W Env protein. This protein is present in the brain of MS patients, is pathogenic and thought to be a key factor in the progression of the disease.

CNNMoney interview

What's the best strategy for Swiss Biotech Start-Ups?

GeNeuro Announces Positive 6-Month Phase IIa Data for GNbAC1 in Adults with Type 1 Diabetes

Geneva, Switzerland, 26 September 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced that its Phase IIa study of GNbAC1 in type 1 diabetes (T1D) met the primary endpoint of safety in this new patient population. GNbAC1 is a monoclonal antibody designed to neutralize a pathogenic envelope protein, pHERV-W Env, which has been detected post mortem in about two thirds of the pancreas of patients with T1D.

GeNeuro Reports 2018 Half-Year Results and Provides Corporate Update

 

Robust cash position of €17.3 million as of June 30, 2018

All clinical and research activities funded through 3Q2019

GeNeuro Reports 2018 Half-Year Results and Provides Corporate Update

 

Robust cash position of €17.3 million as of June 30, 2018

All clinical and research activities funded through 3Q2019

GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier

Based on R&D strategic reasons, Servier declines option to license and to further fund the development of GNbAC1 in MS

Following positive Phase IIb 12-month results, GeNeuro will pursue further development and worldwide partnering options

GeNeuro: financial information and business update for the second quarter 2018

GeNeuro today issued a business update and reported on its cash position and 2018 first-quarter revenues.


Results 1-10 of 20      Next Page      Last Page